Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors—the PAC-WOMAN trial - Takeaways - MDSpire

Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors—the PAC-WOMAN trial

  • By

  • Inês Nobre

  • Marlene N. Silva

  • Sofia Franco

  • Bruno Rodrigues

  • Pedro F. Silva

  • Pedro J. Teixeira

  • Eliana V. Carraça

  • May 14, 2026

  • 0 min

Share

  • 1

    Breast cancer survivors on aromatase inhibitors face a high risk of musculoskeletal pain, with treatment cessation rates between 13% and 22%.

  • 2

    Key predictors of baseline pain intensity include having a partner, poor sleep quality, and longer Timed-up-and-go test durations.

  • 3

    At 4 months, decreased sleep quality, reduced chest press strength, and participation in brief physical activity counseling predict increased pain.

  • 4

    Involvement in brief physical activity counseling and waitlist control groups forecasts greater pain intensity changes compared to exercise groups.

  • 5

    The study highlights the need for longitudinal research to understand pain dynamics in breast cancer survivors and improve intervention strategies.

Original Source(s)

Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors—the PAC-WOMAN trial

  • by Inês Nobre, Marlene N. Silva, Sofia Franco, Bruno Rodrigues, Pedro F. Silva, Pedro J. Teixeira, Eliana V. Carraça

  • May 14, 2026

Related Content

Successful reversal of hepatic visceral crisis in HER2-positive metastatic breast cancer: a case report

Breast, Cervical, and Colorectal Cancer Screening Rates in Women Aged 45 to 64 Years

Glandular tissue–based versus anatomical landmark–based CTV delineation in postoperative breast cancer radiotherapy: a dosimetric comparison